The Latest Research Progress on Myelodysplastic Syndrome Patient-derived Mesenchymal Stem Cell--Review.
10.19746/j.cnki.issn.1009-2137.2022.04.051
- Author:
Fan LI
1
;
Hai-Ping HE
2
;
Li-Hua ZHANG
1
;
Xiao-Sui LING
1
Author Information
1. Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan Province, Kunming 650500, Yunnan Province, China.
2. Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan Province, Kunming 650500, Yunnan Province, China E-mail: 2398230256@qq.com.
- Publication Type:Review
- Keywords:
cytokine;
gene;
mesenchymal stem cell;
microenvironment;
myelodysplastic syndrome;
signaling pathway
- MeSH:
Cytokines/metabolism*;
DEAD-box RNA Helicases/metabolism*;
Hematologic Neoplasms/metabolism*;
Humans;
Mesenchymal Stem Cells;
Myelodysplastic Syndromes/genetics*;
Phosphatidylinositol 3-Kinases/metabolism*;
Ribonuclease III/metabolism*;
Tumor Microenvironment
- From:
Journal of Experimental Hematology
2022;30(4):1286-1290
- CountryChina
- Language:Chinese
-
Abstract:
Myelodysplastic syndrome (MDS) are a heterogeneous group of hematological malignancies. Currently, in addition to demethylated chemotherapy and hematopoietic stem cell transplantation, MDS patient-derived mesenchymal stem cells (MDS-MSC) play an important role in understanding the pathogenesis of MDS and related therapeutic targets. For example, abnormal expression of DICER1 gene, abnormalities of PI3K/AKT and Wnt/β-catenin signaling pathways provide new therapeutic targets for MDS. In addition, MDS-MSC is also affected by abnormal microenvironment of the body, such as inflammatory factor S100A9, as well as hypercoagulation and iron overload. In this review, genes, signaling pathways, cytokines, hematopoietic microenvironment, and the effect of therapeutic drugs for MDS-MSC were briefly summarized.
